XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

NCT06980155 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: Personalized neoantigen tumor vaccine
BIOLOGICAL: PD-1 inhibitor

Sponsor

Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]